Same medicine, same puff of air. The patents mostly sit on the plastic device — and the 2024 Senate investigation laid the gap out in single lines. Honestly sorted, with every figure dated and sourced.
Structured with AI assistance and strictly fact-checked by our editorial team against primary sources. How we work →
Figures come from CMS's NADAC pharmacy-acquisition database, the 2024 Senate HELP investigation record, the UK Drug Tariff, France's ANSM database, India's NPPA price ceiling, Ontario's public formulary, and peer-reviewed research. Where a number is a dated record, we say so — the $7 France figure is from the Senate's 2024 letters; the $497 US figure is current 2026 acquisition data.
| Market | Figure | Context | Source |
|---|---|---|---|
| United States | ~$497 / inhaler (2026 acquisition) | CMS's NADAC database prices Combivent Respimat at $124.29 per gram as of January 2026 — about $497 for the standard 4g/120-dose inhaler at pharmacy acquisition. The 2024 Senate investigation logged US list prices of $200–$600 across brand inhalers: Advair $319, QVAR $286, Combivent $489. | CMS NADAC (Jan 2026) · Senate HELP (2024) |
| France | $7 (Senate record, 2024) | The same Combivent inhaler appeared at $7 in France in the Senate's 2024 letters. France's own medicines database lists salbutamol (Ventoline) at about €3.41–€4.43 with 65% reimbursed — one negotiated national price. | US Senate HELP (2024) · ANSM |
| UK · Germany · Canada · India | £1.50 · $9 · CAD $6 · ~$1.20 | The UK Drug Tariff lists a 200-dose Ventolin at £1.50 base price (Dec 2025). Germany paid $9 for the QVAR that costs $286 in the US (Senate, 2024). Ontario's public plan lists Ventolin at about CAD $6. India's government caps salbutamol inhalers near ₹100 (~$1.20) — and manufacturers still turn a profit. | NHSBSA · Senate HELP · Ontario ODB · NPPA (2025) |
| The catch — the $35 caps | voluntary, with holes | After the 2024 Senate investigation, three of the four companies (not Teva) announced $35 monthly caps. But they're voluntary company programs, not law; Medicare/Medicaid patients are generally excluded; and the Flovent authorized generic ($150–$250) sits outside them. Insured patients already averaged $11 generic / $33 brand per fill in 2023 claims. | Peterson-KFF · Senate report |
We compare what the inhaler costs, not what anyone should take, switch, or stop. Rescue and controller inhalers are different medicines with different roles — treatment decisions belong with you, your pharmacist, and a licensed prescriber.
When researchers at Health Affairs reviewed every inhaler the FDA approved in the modern era — 62 of them between 1986 and 2020 — they found nearly all were brand-name, each shielded from generic competition for a median of 16 years. The tell: more than half of those patents didn't cover the drug at all. They covered the device — the casing, the dose counter, the mouthpiece. Move an old, off-patent medicine into a slightly new device and the monopoly resets; researchers call it device hopping. It's why Advair's first generic didn't arrive until 2019, and why Mylan said getting there cost more than $700 million.
The CFC propellant ban that took effect at the end of 2008 was environmental policy — but the cheap generic albuterol inhalers ran on exactly that propellant, and when the ban hit, they disappeared, leaving only patented brand versions. One JAMA Internal Medicine study measured out-of-pocket albuterol costs rising from $13.60 to $25 per prescription — an 81% jump for privately insured patients. A substitutable generic didn't return until February 2020. That's a 12-year blackout on one of the oldest, cheapest respiratory medicines on earth.
After the Senate HELP Committee opened its investigation in January 2024 and published the arbitrage in single lines — Advair $319 here, $26 in Britain; QVAR $286 here, $9 in Germany; Combivent $489 here, $7 in France — three of the four companies announced $35 monthly caps within months. Teva never committed. The caps are voluntary programs, not law; Medicare and Medicaid patients are generally excluded; and when GSK pulled Flovent on the exact day a new Medicaid rebate rule took effect (January 1, 2024), the authorized generic that replaced it listed at $150–$250 and sat outside the caps entirely — a move a Senate report estimated avoided roughly $367.6 million a year in rebates. The honest ending: the first true generic Flovent cleared the FDA in March 2026, and roughly 1 in 6 American adults with asthma still reports skipping or stretching medication because of cost.
Combivent Respimat runs about $497 at US pharmacy acquisition (CMS NADAC, January 2026) versus $7 in France per the 2024 Senate record. Advair: $319 US vs $26 UK. QVAR: $286 US vs $9 Germany (Senate HELP, 2024). The UK base price for a 200-dose Ventolin is £1.50 (NHSBSA Drug Tariff, Dec 2025).
Researchers reviewed all 62 inhalers the FDA approved between 1986 and 2020: median 16 years of protection from generic competition, and more than half the patents covered the delivery device, not the drug (Health Affairs). Moving an old medicine into a slightly new device resets the monopoly — researchers call it device hopping.
The 2008 CFC propellant ban removed generic albuterol from shelves; out-of-pocket costs jumped from $13.60 to $25 per prescription (2004–2008, JAMA Internal Medicine, +81% for privately insured patients), and the first substitutable generic HFA albuterol only arrived in 2020 (FDA) — a 12-year generic gap.
Partially. They're voluntary company programs, not law: Boehringer Ingelheim and AstraZeneca from June 2024, GSK by January 2025 — Teva made no commitment, and Medicare/Medicaid patients are generally excluded (Peterson-KFF). Insured patients already averaged $11 for a generic fill and $33 for a brand in 2023 claims data.
GSK discontinued Flovent on January 1, 2024 — the day a new Medicaid rebate rule took effect — and switched to an authorized generic through a partner. A Senate report estimated the move let GSK avoid roughly $367.6 million a year in Medicaid rebates; the authorized generic listed at $150–$250 a month and wasn't covered by the $35 caps. The first true generic fluticasone cleared the FDA in March 2026 (Glenmark).
India's national price ceiling puts salbutamol inhalers at roughly ₹100 (~$1.20) per inhaler (NPPA, 2025) — and manufacturers still sell profitably at that level. The UK's base price for a 200-dose Ventolin is £1.50; Ontario's public plan lists it near CAD $6. Cost information, not medical advice — inhaler decisions belong with your prescriber and pharmacist.
Wellness Vision does not sell medication, book trips, or take referrals. Every figure above traces to the public sources cited — a federal pricing database, a Senate investigation record, peer-reviewed journals, regulators, and official tariffs. This is a cost comparison, not medical advice: nothing here tells anyone to start, stop, switch, or ration an inhaler, and asthma or COPD treatment decisions belong with you, your pharmacist, and a licensed prescriber.
📋 Or get the free Medical Cost Checklist — no email →
View provenance manifest for this video →
You shouldn't have to go broke to feel whole.
